Paracoccidioides HSP90 can be found in the cell surface and is a target for antibodies with therapeutic potential

Paracoccidioidomycosis (PCM) is one of the most frequent systemic mycoses in Latin America. It affects mainly male rural workers in impoverished regions, and the therapy can last up to two years or use drugs that are very toxic. Given the need for novel safe and effective approaches to treat PCM, we...

Full description

Main Authors: Moura, Ágata Nogueira D’Áurea, Oliveira, Diane Sthefany Lima de, Paredes, Verenice, Rocha, Leticia Barboza, Oliveira, Fabiana Freire Mendes de, Lessa, Gustavo Meirelles, Riasco Palacios, Juan Fernando, Casadevall, Arturo, Albuquerque, Patrícia, Felipe, Maria Sueli Soares, Piazza, Roxane Maria Fontes, Nicola, André Moraes
Format: Artigo
Language: Inglês
Published: MDPI 2021
Subjects:
Online Access: https://repositorio.unb.br/handle/10482/40940
https://doi.org/10.3390/jof6040193
https://orcid.org/0000-0003-0480-5028
https://orcid.org/0000-0002-2655-4672
https://orcid.org/0000-0001-7832-058X
https://orcid.org/0000-0002-9170-1034
https://orcid.org/0000-0002-9402-9167
https://orcid.org/0000-0001-8160-7784
https://orcid.org/0000-0001-8656-5835
Tags: Add Tag
No Tags, Be the first to tag this record!
Summary: Paracoccidioidomycosis (PCM) is one of the most frequent systemic mycoses in Latin America. It affects mainly male rural workers in impoverished regions, and the therapy can last up to two years or use drugs that are very toxic. Given the need for novel safe and effective approaches to treat PCM, we have been developing monoclonal antibodies (mAbs) that could be used not only to block specific fungal targets, but also modulate the host’s antifungal immunity. In this work we show the generation of and promising results with an mAb against Heat Shock Protein (HSP)90, a molecular chaperone that is an important virulence factor in fungi. Using recombinant Paracoccidioides lutzii (Pb01) and P. brasiliensis (Pb18) HSP90 proteins produced in E. coli, we immunized mice and generated polyclonal antibodies and an IgG1 hybridoma mAb. The proteins were very immunogenic and both the polyclonal serum and mAb were used in immunofluorescence experiments, which showed binding of antibodies to the yeast cell surface. The mAb successfully opsonized P. lutzii and P. brasiliensis cells in co-incubations with J774.16 macrophage-like cells. Our results suggest that this mAb could serve as the basis for new immunotherapy regimens for PCM.